How close are we to eradicating HIV Philip A. Chan

The world is getting closer

to achieving one of the most important
public health goals of our time:

eradicating HIV.

And to do this, we won’t even have
to cure the disease.

We simply have to stop HIV from
being transmitted

until eventually it fizzles out.

Once, this goal would have
seemed impossible.

HIV has caused millions of deaths

and is one of the most devastating
diseases that humanity has ever known.

But we’re now at a point where new
advances

such as one-pill, once-a-day medications

are helping us tackle HIV
in effective ways.

HIV is a retrovirus–

meaning it integrates copies of itself
into an infected cell’s DNA,

allowing it to replicate and
infect other cells.

HIV has evolved numerous ways to evade
the human immune system,

which makes it difficult to cure.

But by developing ways to
block HIV replication,

we can stop the spread of HIV itself.

That’s where antiretrovirals–
a.k.a. ARVs– come in.

ARVs are a group of drugs which work
in different ways to combat HIV.

Some block HIV’s access into immune cells,

and others work by stopping the
virus itself from replicating.

ARVs also work preventatively in people
who don’t have HIV.

This type of approach is called
pre-exposure prophylaxis, or PrEP.

PrEP works by accumulating in a
person’s body

and preventing HIV from
establishing itself.

That means an HIV-negative person who may
be at risk of contracting the disease

can take certain ARVs
to protect themselves,

before they become exposed.

Here’s where it gets
especially interesting:

In people with HIV, ARVs can also
dramatically reduce HIV transmission.

This is called “Treatment as Prevention.”

On a global scale, this has the potential
to end the HIV epidemic.

It’s based on the idea that someone with
HIV who takes ARV’s

can lower the virus level in their bodies
until it becomes undetectable.

That doesn’t mean the virus is gone;

it could still be lurking within cells,
ready to reactivate if treatment stops.

But so long as it’s kept
dormant with drugs,

HIV remains undetectable.

And when HIV is undetectable,
it’s untransmittable, too.

In theory this means that by testing
everyone who’s at risk of HIV

and treating those who test positive,

we could stop transmission and
eventually eradicate HIV.

In the real world, however,
things are more complex.

Many at-risk HIV negative people across
the world

do not have access to PrEP or ARVs,

and those who are HIV positive may
experience challenges to taking ARVs.

These problems are often greatest in
countries

where the burden of HIV is highest.

Getting these medications depends on
access to a functioning healthcare system–

and this isn’t something everyone has.

That’s part of the reason why stopping
the spread of HIV for good

will require a significant investment of
resources to improve those systems.

One study carried out by the UNAIDS

estimated that between 20-30 billion
dollars per year

would be needed to achieve
a nearly 90% reduction

in new HIV infections by 2030.

This investment would ensure more people
would get tested in the first place,

and more would be able to access and
maintain treatment.

Achieving this goal and improving
healthcare in general

is in everyone’s best interest,

from individual people to
society as a whole.

We have roadmaps that could allow us

to bring the HIV epidemic to an
end in the near future,

with the possibility of eradicating the
disease altogether

several generations in the future.

In the period from 1996 to 2017

we almost halved the number
of new HIV infections,

and for the millions of people who still
live with the virus,

ARV treatments enable most to lead long
and healthy lives.

With continued and increased investments,

we can get transmission rates low enough
to end HIV once and for all.

A world without HIV is no longer
inconceivable:

it’s closer than ever.

世界越来越

接近实现我们这个时代最重要的
公共卫生目标之一:

根除艾滋病毒。

要做到这一点,我们甚至
不必治愈这种疾病。

我们只需要阻止艾滋病毒
的传播,

直到它最终消失。

曾经,这个目标
似乎是不可能的。

艾滋病毒已导致数百万人死亡

,是人类已知的最具破坏性的
疾病之一。

但我们现在正处于一个新
进展

,例如一天一次的单片药物

正在帮助我们
以有效的方式应对艾滋病毒。

HIV 是一种逆转录病毒——

这意味着它将自身的副本
整合到受感染细胞的 DNA 中,

使其能够复制并
感染其他细胞。

HIV已经进化出许多
逃避人类免疫系统的方法,

这使得它很难治愈。

但是通过开发
阻止 HIV 复制的方法,

我们可以阻止 HIV 本身的传播。

这就是抗逆转录病毒药物——也就是抗逆转录病毒药物——
发挥作用的地方。

抗逆转录病毒药物是一组
以不同方式对抗艾滋病毒的药物。

一些阻止 HIV 进入免疫细胞,

而另一些则通过阻止
病毒本身复制来发挥作用。

抗逆转录病毒药物也
对没有艾滋病毒的人起到预防作用。

这种类型的方法称为
暴露前预防,或 PrEP。

PrEP 的作用是在
人体内积累

并防止 HIV
自行建立。

这意味着可能
有感染该疾病风险的 HIV 阴性者可以在暴露前

服用某些抗逆转录病毒药物
来保护自己

这里
是特别有趣的地方:

在艾滋病毒感染者中,抗逆转录病毒药物还可以
显着减少艾滋病毒的传播。

这被称为“以治疗为预防”。

在全球范围内,这有
可能结束艾滋病毒的流行。

这是基于这样一种观点,即
服用抗逆转录病毒药物的 HIV 感染者

可以降低体内的病毒水平,
直到无法检测到。

这并不意味着病毒消失了。

它可能仍潜伏在细胞内,
准备好在治疗停止时重新激活。

但只要它
在药物中保持休眠状态,

艾滋病毒就仍然无法检测到。

当 HIV 无法检测到时,它也无法传播

从理论上讲,这意味着通过检测
所有有感染艾滋病毒风险的

人并治疗检测呈阳性的人,

我们可以阻止传播并
最终根除艾滋病毒。

然而,在现实世界中,
事情要复杂得多。 世界

各地许多高危 HIV 阴性

者无法获得 PrEP 或 ARV,

而 HIV 阳性者可能会
在服用 ARV 时遇到挑战。

艾滋病毒负担最高的国家,这些问题往往最为严重。

获得这些药物取决于
能否获得功能正常的医疗保健系统——

而这并不是每个人都拥有的。

这就是为什么要永久
阻止艾滋病毒传播

需要大量
资源投资来改善这些系统的部分原因。

联合国艾滋病规划署进行的一项研究

估计,到 2030
年,每年

需要 20-300 亿美元才能将

新的艾滋病毒感染减少近 90%。

这项投资将确保更多的人
首先接受检测,

而且更多 将能够获得和
维持治疗。

实现这一目标并
总体上改善医疗保健

符合每个人的最大利益,

从个人到
整个社会。

我们有路线图,可以让我们在不久的

将来结束艾滋病毒的流行

并有可能

在未来几代人中彻底根除这种疾病。

在 1996 年至 2017 年期间,

我们几乎将新感染艾滋病毒的人数减少了一半

,对于仍然感染病毒的数百万人来说

抗逆转录病毒治疗使大多数人能够过上长寿
和健康的生活。

随着投资的持续和增加,

我们可以将传播率降低到足以
一劳永逸地结束艾滋病毒的程度。

一个没有艾滋病毒的世界不再是
不可思议的:

它比以往任何时候都更接近。